MP Advisors/Mehta Partners: Indian BioPharma Landscape – 2018

It is our pleasure to share with you our recent update on India’s BioPharmaceutical Landscape. We have developed this evolving framework that has helped us assess various pharma markets and companies regardless of geography—an integrated perspective to help identify value drivers and global growth opportunities. 

Indian companies have predominantly thrived on globalizing their generic formulations business with a primary focus on the US market.  However, increasing pricing pressure as a result of consolidation among payer groups and PBMs (Pharma Benefit Managers), and intensifying competition call for different growth strategies to build on their generics foundation, Innovation and Biosimilars to name a few.  As you know, the MP Group has successfully monitored these growth avenues and identified attractive opportunities. The current presentation gives an overview of the Indian Pharma Industry, which will be followed by deep dive of the some of the high impact areas in the coming months.

You too would be exploring both innovation and biosimilar opportunities and we would be delighted to share our insights to help you advance your strategy, and look forward to your feedback.

Please download MPGroup – Indian BioPharma Landscape – 2018. We would appreciate any queries/comments from your side. 

Leave a Reply

Close Menu